Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.mehy.2020.110307

http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110307
suck pdf from google scholar
33035967!7834646!33035967
unlimited free pdf from europmc33035967    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid33035967      Med+Hypotheses 2020 ; 145 (ä): 110307
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19, myocardial edema and dexamethasone #MMPMID33035967
  • Rafiee MJ; Babaki Fard F; Friedrich MG
  • Med Hypotheses 2020[Dec]; 145 (ä): 110307 PMID33035967show ga
  • Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the cause of coronavirus disease- 2019 (COVID-19) after emerging in china in late 2019 is spreading rapidly across the world. The most common cause of death in patient with COVID-19 is the rapid progression of acute respiratory distress syndrome (ARDS) shortly after the beginning of dyspnea and hypoxemia. Patients with severe COVID-19 may also develop acute cardiac, kidney and liver injury that are associated with poor prognosis and can lead to high mortality rate. Numerous randomized trials are ongoing to find an effective, safe and widely available treatment. Remdisivir is the only FDA -approved antiviral agent for treatment of severe COVID-19. Glucocorticoids (GCs) have been used for treatment of cytokine storm syndrome and respiratory failure in hospitalized patient with severe covid-19. One of the therapeutic effects of GCs is stability of vascular endothelial barrier and decreasing tissue edema. In our opinion, the decreasing vascular permeability effect of glucocorticoids in the injured myocardium might has an important additional factor in reducing mortality in severe, hospitalized COVID-19 patients.
  • |*COVID-19 Drug Treatment[MESH]
  • |Antiviral Agents/therapeutic use[MESH]
  • |COVID-19/*complications[MESH]
  • |Capillary Permeability[MESH]
  • |China/epidemiology[MESH]
  • |Dexamethasone/*therapeutic use[MESH]
  • |Edema/*complications/diagnosis[MESH]
  • |Fibrosis[MESH]
  • |Glucocorticoids/therapeutic use[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Inflammation[MESH]
  • |Myocardium/*pathology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box